Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
FRAME Data Simultaneously Published in New England Journal of Medicine and Presented at ASBMR Showed Treatment With Romosozumab Significantly Reduced New Vertebral and Clinical Fractures Through 12 Months
Significant Bone Mineral Density Gains Shown at Six and 12 Months at the Lumbar Spine, Total Hip and Femoral Neck
Bone Mineral Density Continued to Increase and Vertebral Fracture Risk Reduction Persisted With the Transition From Romosozumab to Denosumab Through 24 Months
THOUSAND OAKS, Calif. and BRUSSELS, Sept. 18, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced findings from the FRAME study showing that the investigational agent romosoz...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news